Paper36947730
The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
McManus HD and 1 other. J Clin Oncol, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer. Papers, record 36947730. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36947730
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Male | |
| Humans | |
| Docetaxel | |
| Hormones | |
| Androgen Antagonists |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 36795843 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. | https://conductscience.org/library/papers/36795843 |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35420921 | Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35420921 | PubMed |
| 2 | 35405085 | Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. | Lancet | 2022 | https://conductscience.org/library/papers/35405085 | PubMed |
| 3 | 35864053 | Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer. | Clin Genitourin Cancer | 2022 | https://conductscience.org/library/papers/35864053 | PubMed |
| 4 | 34030924 | Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. | Eur Urol | 2021 | https://conductscience.org/library/papers/34030924 | PubMed |
| 5 | 29529169 | Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29529169 | PubMed |
| 6 | 11807147 | CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. | N Engl J Med | 2002 | https://conductscience.org/library/papers/11807147 | PubMed |
| 7 | 30987939 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30987939 | PubMed |
| 8 | 2437455 | Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. | N Engl J Med | 1987 | https://conductscience.org/library/papers/2437455 | PubMed |
| 9 | 35179323 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35179323 | PubMed |
| 10 | 30355464 | Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. | Lancet | 2018 | https://conductscience.org/library/papers/30355464 | PubMed |
| 11 | 36795843 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36795843 | PubMed |
| 12 | 29384722 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29384722 | PubMed |
| 13 | 31157964 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31157964 | PubMed |
| 14 | 33914595 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33914595 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42112615 | The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer. | Oncologist | 2026 | https://conductscience.org/library/papers/42112615 | PubMed |
| 42086938 | Managing patients with recurrent prostate cancer who refuse ADT. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/42086938 | PubMed |
| 40862806 | Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40862806 | PubMed |
| 39330003 | Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer. | Curr Oncol | 2024 | https://conductscience.org/library/papers/39330003 | PubMed |
| 38291265 | Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy. | Curr Treat Options Oncol | 2024 | https://conductscience.org/library/papers/38291265 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36947730
GET https://conductscience.org/api/papers/v1/36947730/authors